The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
== Planetary models == In the late 1800s speculations on the possible structure of the atom included planetary models with orbiting charged electrons. These models faced a significant constraint. In 1897, Joseph Larmor showed that an accelerating charge would radiate power according to classical electrodynamics, a result known as the Larmor formula. Since electrons forced to remain in orbit are continuously accelerating, they would be mechanically unstable. Larmor noted that electromagnetic effect of multiple electrons, suitably arranged, would cancel each other. Thus subsequent atomic models based on classical electrodynamics needed to adopt such special multi-electron arrangements. In 1903 Hantaro Nagaoka challenged Thomson's plum pudding model with a "Saturnian" model which featured a massive atomic center with a positive charge of 10,000 times the electron charge, surrounded by electrons in rings analogous to those of Saturn. The model was widely discussed, including a detailed study George Schott which claimed it failed to correctly predict atomic spectra. Nagaoka himself abandoned the proposal in 1908.
(Auxotrophs are usually not temperature-dependent. They can also depend on other factors.) It is also possible that an organism is auxotrophic to more than just one organic compound that it requires for growth.
=== HN tag === The HN tag has alternating histidine and asparagine (HNHNHNHNHNHN) and is more likely to be presented on the protein surface than Histidine-only tags. The HN tag binds to the immobilized metal ion more efficiently than the His tag.
Sources: en.wikipedia.org
== Reactions == Metal carbonyls are important precursors for the synthesis of other organometallic complexes. Common reactions are the substitution of carbon monoxide by other ligands, the oxidation or reduction reactions of the metal center, and reactions at the carbon monoxide ligand.
== History == Modified atmosphere/modified humidity (MA/MH) packaging is a type of equilibrium modified atmosphere packaging (EMAP), which evolved due to the need for more control of humidity in the packaging. Most of the polymers that are commercially used in EMAP are polyolefin-based, characterized by low moisture vapor transmission rate (MVTR). Temperature fluctuations during the various links in the cold logistics chain are unavoidable and will result in condensation forming on the inner surface of the package. The accumulation of condensed water in packages with low MVTR is conducive for pathological and physiological disorders. Not only does excess moisture enhance fungal and bacterial decay and the formation of off odors, it also encourages leaf sprouting in topped root vegetables, regrowth of leaves and physiological disorders such as tissue discoloration and peel blemishes. Certain produce items are more sensitive to excess moisture than others.
=== February === February 5, 2010: Canada Employment increased by 43,000 in January, all in part-time, pushing the unemployment rate down 0.1 percentage points to 8.3%. January marks the fourth employment gain in six months. Despite the recent increases, employment still remains 280,000 below the level of October 2008. Employment gains in January were driven by women aged 25 to 54 and youths. This was the first notable increase for youths since the start of the employment downturn in the fall of 2008. There were large increases in part-time employment in January, bringing it back to the level of six months earlier. Full-time employment was little changed in January, but has trended up over the last six months. January's increase was among private sector employees, while self-employment declined. Over the last six months, the number of private and public sector employees has been rising while self-employment has been little changed. The largest employment increases in January occurred in business, building and other support services, and retail and wholesale trade. These were partially offset by losses in professional, scientific, and technical services, as well as agriculture.
Researchers are investigating biomarkers to help diagnose MS, to inform prognoses, and track response to medication. Ideally, biomarker would be detectable in blood, as cerebrospinal fluid is more difficult to access. Three biomarkers are emerging as candidates for real-world applications: Neurofilament light chain (NfL), chitinase-3-like protein 1 (CHI3L1) and glial fibrillary acidic protein (GFAP). NfL levels are elevated years before people typically get an MS diagnosis, and is of interest as a potential screening tool. GFAP and CHI3L1 may be able to track progression independent if relapse activity, and be used as disease progress markers.
Sources: en.wikipedia.org
Noribogaine is a hERG inhibitor and appears at least as potent as ibogaine. The inhibition of the hERG potassium channel delays the repolarization of cardiac action potentials, resulting in QT interval prolongation and, subsequently, in arrhythmias and sudden cardiac arrest. Ibogaine and the structurally related hallucinogen harmaline are tremorigenic, whereas noribogaine is not or is much less so. Noribogaine, but not ibogaine, produces potent psychoplastogenic effects in vitro in preclinical research. This can be blocked by the serotonin 5-HT2A receptor antagonist ketanserin, by the mTOR inhibitor rapamycin, and by a TrkB antagonist.
== Description == Cmax is the opposite of Cmin, which is the minimum (or trough) concentration that a drug achieves after dosing. The related pharmacokinetic parameter tmax is the time at which the Cmax is observed. After an intravenous administration, Cmax and tmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration, Cmax and tmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject. Short term drug side effects are most likely to occur at or near the Cmax, whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the Cmin. The Cmax is often measured in an effort to show bioequivalence (BE) between a generic and innovator drug product. According to the FDA, drug quality bioavailability (BA) and BE rely on pharmacokinetic measurements such as AUC and Cmax that are reflective of systemic exposure.
9 May A record annual increase in atmospheric CO2 is reported from the Mauna Loa Observatory in Hawaii, with a jump of 4.7 parts per million (ppm) compared to a year earlier. A cubic millimetre of the human brain is mapped at nanoscale resolution by a team at Google. This contains roughly 57,000 cells and 150 million synapses, incorporating 1.4 petabytes of data. A study in Physical Review Letters concludes that the black hole in VFTS 243 likely formed instantaneously, with energy mainly expelled via neutrinos. This means it would have skipped the supernova stage entirely. An analysis of ocean protection for the global conservation target to protect at least 30% of the ocean by 2030 (30 by 30), finds around a quarter of marine protected area (MPA) coverage is not implemented, and one-third is incompatible with the conservation of nature due to the occurrence of highly destructive activities. According to the study, indicators of MPA quality, not only coverage, are needed. On 11 June, a study finds MPAs' effectiveness is not determined by any specific governance approaches or incentives, but the combination of many different integrated incentives. 10 May – A series of solar storms and intense solar flares impact the Earth, creating aurorae at more southerly and northerly latitudes than usual. 13 May – OpenAI reveals GPT-4o, its latest AI model, featuring improved multimodal capabilities in real time. 15 May Astronomers report an overview of preliminary analytical studies on returned samples of asteroid 101955 Bennu by the OSIRIS-REx mission.
== Breeding purposes == It will hybridize with common domestic tomatoes. There are annual, biennial, and perennial varieties. Solanum pimpinellifolium is important in tomato breeding. Its relatedness to tomatoes and ability to freely cross with them has allowed it to be used for the introduction of disease resistance traits in tomato varieties, as well as in the study of the genetic control of tomato traits such as fruit shape and size. It has higher amounts of lycopene, vitamin C, and phenolic acids, as well as a higher antioxidant capacity than Solanum lycopersicum. Its 900 Mb genome differs from the tomato at 0.6% of base pairs; in comparison, they both differ from the potato (from which they diverged 7.3 million years ago) at 8% of bases. In addition to its utilization in common tomato breeding, S. pimpinellifolium has also been the target of attempted de novo domestication, with the intent to create a separate domesticated species. This includes the use of CRISPR gene editing to replace 6 domestication-related loci, resulting in plants with altered architecture, and larger, more numerous fruits. Considered the ancestor of domesticated tomatoes, it is valued for supplementing the limited gene pool of the domestic tomato. Due to agricultural development, the wild currant tomato is becoming less prevalent in the native range of northern Peru and southern Ecuador.
The history of the U.S. legislation on AAS goes back to the late 1980s, when the U.S. Congress considered placing AAS under the Controlled Substances Act following the controversy over Ben Johnson's victory at the 1988 Summer Olympics in Seoul. AAS were added to Schedule III of the Controlled Substances Act in the Anabolic Steroids Control Act of 1990. The same act also introduced more stringent controls with higher criminal penalties for offenses involving the illegal distribution of AAS and human growth hormone. By the early 1990s, after AAS were scheduled in the U.S., several pharmaceutical companies stopped manufacturing or marketing the products in the U.S., including Ciba, Searle, Syntex, and others. In the Controlled Substances Act, AAS are defined to be any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promote muscle growth. The act was amended by the Anabolic Steroid Control Act of 2004, which added prohormones to the list of controlled substances, with effect from 20 January 2005. Even though they can still be prescribed by a medical doctor in the U.S., the use of anabolic steroids for injury recovery purposes has been a taboo subject, even amongst the majority of sports medicine doctors and endocrinologists.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.